EDXC Endexx Corporation (PK)

Endexx, along with C3 Global Biosciences, Inc., a cause-driven organization committed to developing sustainable health solutions through the advancement of cannabis science, will be sponsoring Athletes For Care (A4C), newly formed 501c3 non-profit dedicated to creating a community where athletes can find support, opportunity and purpose in life after a career in sports. As part of the sponsorship, both companies will be hosting an educational workshop focused on the active lifestyle cannabis user and expand upon the notion of cannabis as a medicine or therapy to explore cannabis as a general health and wellness supplement for the active lifestyle. 

Endexx CEO Todd Davis commented, "Through scientific process and education, we have learned more about Chronic Traumatic Encephalopathy (CTE), a degenerative brain disease found in athletes, military veterans, and others with a history of repetitive brain trauma. This has become a primary concern for mental and physical health of the community. Moving forward, Endexx and C3 will support scientific teams and organizations such as A4C in the pursuit of medical support and prevention of serious brain trauma that so many have suffered from." 

C3 Global Biosciences CEO Andrew Serafini explains, "Scientific validation leads to standardization and democratization, while ensuring good practices invariably results in markedly improved patient outcomes. Cannabidoil (CBD) can serve as an initial line of therapy in many disease states as well as chronic treatment, allowing for tapering off dangerous medications and promoting proactive wellness." 

In recent history, former NFL players have been diagnosed with CTE. Symptoms and changes in mental health include suicidal behavior, violence, chronic pain, opioid addiction and poor quality of life. CBD offers the scientific community and medical professionals a natural tool to support the treatment and long-term health of the people afflicted with these conditions. Continuous research must be supported to fully understand the endocannabinoid system and its support of functionality throughout the human body. HJ Raza, MD/PhD, Chief Medical Officer of C3GBS, will be demonstrating technology at the show that will allow doctors to scientifically validate the science and health benefits of CBD in cases of neurological damage and disease. See Video: http://www.marketwatch.com/video/sectorwatch/this-medical-device-scans-your-brain-on-marijuana/320FC472-6DA8-4AE4-8D5D-0465D78EC58C.html. The schedule will be announced later this week.

About Endexx

Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. Phyto-Bites®, is its CBD-infused soft chews for dogs. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation. The company also has two technology products and services that launched in 2014 -- the M3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through "seed to sale" inventory management and an "End of Sale" technology integration. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to eventual federal mandates. The Autospense™ is a commercial grade inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers. Websites include: www.cbdunlimited.com, www.endexx.com, www.phytobites.com.

See: www.C3globalbiosciences.com

Safe Harbor Notice
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.